+

WO1996040064A1 - Formulations liposomales contenant de la cyclosporine, utilisees comme agents immunosuppresseurs et pour le traitement de multiples cas pharmacoresistants - Google Patents

Formulations liposomales contenant de la cyclosporine, utilisees comme agents immunosuppresseurs et pour le traitement de multiples cas pharmacoresistants Download PDF

Info

Publication number
WO1996040064A1
WO1996040064A1 PCT/US1996/009053 US9609053W WO9640064A1 WO 1996040064 A1 WO1996040064 A1 WO 1996040064A1 US 9609053 W US9609053 W US 9609053W WO 9640064 A1 WO9640064 A1 WO 9640064A1
Authority
WO
WIPO (PCT)
Prior art keywords
liposomes
cyclosporin
phosphatidylcholine
cholesterol
liposomal
Prior art date
Application number
PCT/US1996/009053
Other languages
English (en)
Inventor
Karen L. Moynihan
Jill Adler-Moore
Su-Ming Chiang
Original Assignee
Nexstar Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/472,635 external-priority patent/US5656287A/en
Priority claimed from US08/475,294 external-priority patent/US5693336A/en
Application filed by Nexstar Pharmaceuticals, Inc. filed Critical Nexstar Pharmaceuticals, Inc.
Priority to AU60479/96A priority Critical patent/AU6047996A/en
Publication of WO1996040064A1 publication Critical patent/WO1996040064A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant

Definitions

  • This invention relates to the fields of biochemistry and medicine, and in particular to a novel liposomal formulation and process. More specifically, it relates to a liposomal formulation containing the immunosuppressive agent cyclosporine and to its process of manufacture. This invention also relates to a liposomal cyclosporine formulation having reduced toxicity, increased shelf life stability and increased stability in the blood of mammals.
  • Cyclosporine also known as cyclosporin A
  • Cylindrocapon lucidum Booth was isolated from two strains of imperfect fungi, Cylindrocapon lucidum Booth and Tolypocladium inflatum Gams.
  • Cyclosporins are hydrophobic, neutral, cyclical peptides which have essentially similar chemical and physical characteristics. Cyclosporine is a representative example, and consists of eleven amino acids with a total molecular weight of 1201. Cyclosporine is soluble in methanol, chloroform and ether and essentially insoluble in water. It is supplied for therapeutic purposes as either an intravenous preparation dissolved in a proprietary castor oil and alcohol, or an oral formulation dissolved in Labrophil and olive oil. Cyclosporine is primarily used for treating allograft patients and has been used in experimental trials for autoimmune diseases. The use of this drug has greatly increased the survival rate of transplant patients since its advent in 1978.
  • cyclosporine is a very useful immunosuppressive agent, it can also be highly toxic when used for prolonged periods of time and/or at high doses, both of which are necessary to ensure graft acceptance.
  • the most severe side effect associated with cyclosporine therapy is drug-induced nephrotoxicity.
  • Vascular interstitial toxicity is the most common form of cyclosporine nephrotoxicity and can manifest itself as three different morphological lesions, occurring either alone or in combination.
  • morphological changes associated with cyclosporine nephrotoxicity are unique to cyclosporine toxicity, if they are observed in combination with one another and there is also a corresponding high level of serum cyclosporine, the damage is probably a result of cyclosporine toxicity.
  • Renal toxicities can be monitored serologically by following the increase in creatinine levels.
  • the increase in creatinine level is probably a direct result of arteriole constriction and blockage which would result in lower glomerular filtration rate and thus an increase in serum creatinine.
  • Cremophor -El is a polyoxyethylated castor oil that is one of the best ionic surfactants used to dissolve lipophilic drugs.
  • the most common of the adverse reactions associated with CreL administration has been anaphylaxis which results from a rapid release of histamine and causes increasing hypertension. It is also believed that part of the nephrotoxicity associated with cyclosporine treatment may be enhanced by CreL deposition and crystal formation within the kidney tubules.
  • Other studies have also shown a decrease in both renal blood flow and creatinine clearance in animals treated with CreL. Riconic acid, a component of CreL, has been shown to cause vasoconstriction which could also be linked to hypertension and decreased glomerular blood flow.
  • Liposomes are microscopic delivery vesicles made, in part, from phospholipids which form closed, fluid filled spheres when mixed with water.
  • Phospholipid molecules are polar, having a hydrophilic ionizable head, and a hydrophobic tail consisting of long fatty acid chains.
  • the tails spontaneously associate to exclude water while the hydrophilic phosphate heads interact with water.
  • the result is a bilayer membrane in which the fatty acid tails converge in the newly formed membrane's interior and the polar heads point in opposite directions toward an aqueous medium.
  • the polar heads at one surface of the membrane point toward the aqueous interior of the liposome.
  • the polar heads interact with the surrounding aqueous medium.
  • water soluble molecules will be incorporated into the aqueous interior, and lipophilic molecules will tend to be incorporated into the lipid bilayer.
  • Liposomes may be either multilamellar, like an onion with liquid separating many lipid bilayers, or unilamellar, with a single bilayer surrounding an entirely liquid center.
  • liposome preparation techniques which may be employed and which produce various types of liposomes. These can be selected depending on the use, the chemical intended to be entrapped, and the type of lipids used to form the bilayer membrane. Those parameters which must be considered in producing an optimal liposome preparation are similar to those of other controlled release mechanisms. They are as follows: (1) high percent of chemical entrapment; (2) increased chemical stability; (3) low chemical toxicity; (4) rapid method of production; and (5) reproducible size distribution. The first method described to encapsulate chemicals in liposomes involved production of multilameUar vesicles (MLVs).
  • MLVs multilameUar vesicles
  • the MLV process involves dissolving the lipid components in a suitable solvent, evaporation of the solvent to form a dry lipid film, and hydration of the lipid film with an aqueous medium.
  • the multilamellar vesicles which form are structures having generally more than three concentric bilayers. Lipophilic drugs are incorporated into the MLVs by codissolution of the drugs in the solvent phase, while hydrophilic drugs are entrapped between the bilayers with the hydration buffer. By increasing the length of time of hydration and gentle shaking of the resuspending lipid film, one can achieve a higher proportion of the aqueous phase per mole of lipid, and thus enhance hydrophilic drug encapsulation.
  • Liposomes can also be formed as unilamellar vesicles (UVs), which have diameters up to 2 ⁇ m, but generally less than 1 ⁇ m.
  • UVs unilamellar vesicles
  • unilamellar liposomes there are several techniques which are used to produce unilamellar liposomes.
  • Large unilamellar vesicles can be formed using the reverse-phase evaporation method. This is done by removing the organic phase of a sonicated emulsion of phospholipid, buffer and excess organic solvent under pressure. This technique is especially useful for encapsulating large volumes of aqueous phase containing hydrophilic molecules, such as ferritin, 25S RNA or SV-40 DNA.
  • Maximum encapsulation of the LUV aqueous phase (65%) can be obtained if the ionic strength of the aqueous buffer is low (0.01 M NaCl); encapsulation decreases to 20% as the ionic strength is increased to 0.5 M NaCl.
  • the size of the LUVs varies with the lipid and cholesterol content.
  • Vesicles formed from cholesterol and phospholipid with a 1 : 1 mole ratio form a heterogeneous size distribution of vesicles with a mean diameter, based upon entrapped volume, of 0.47 ⁇ m and a size range of 0.17-0.8 ⁇ m.
  • Vesicles prepared from similar phospholipid mixtures lacking cholesterol have a mean size of 0.18 ⁇ m and a size range of 0.1 -0.26 ⁇ m.
  • the solvent infusion evaporation method can produce both larger or smaller
  • UVs depending on variations in the technique.
  • phospholipids are dissolved in diethylether and injected into a buffer maintained at 55-65°C containing the material to be entrapped or injected.
  • the mixture is kept under vacuum at 30°C.
  • vesicles are formed.
  • the range in diameter of these vesicles is from 0.25- 1 ⁇ m. This procedure is well suited for entrapment of large molecules.
  • Smaller unilamellar vesicles can also be formed using a variety of techniques. By dissolving phospholipids in ethanol and injecting them into a buffer, the lipids will spontaneously rearrange into unilamellar vesicles. This provides a simple method to produce UVs which have internal volumes similar to that of those produced by sonication (0.2-0.5 L/mol/lipid). Sonication or extrusion (through filters) of MLVs also results in dispersions of UVs having diameters of up to 0.2 ⁇ m, which appear as clear or translucent suspensions. Another common method for producing small UVs is the detergent removal technique.
  • Phospholipids are solubilized in either ionic or non-ionic detergents such as cholates, Triton X, or n-alkylglucosides.
  • the drug is then mixed with the solubilized lipid- detergent micelles.
  • Detergent is then removed by one of several techniques: dialysis, gel filtration, affinity chromatography, centrifugation or ultrafiltration. The size distribution and entrapment efficiencies of the UVs produced this way will vary depending on the details of the technique used. Also, when protein is entrapped, there is no certainty that once the detergent has been removed, the protein will renature into its native bioactive conformation.
  • liposomes can include the delivery of drugs which are normally very toxic in the free form. In the liposomal form the toxic drug may be directed away from the sensitive tissue and targeted to selected areas. Liposomes can also be used therapeutically to release drugs slowly, over a prolonged period of time, reducing the frequency of administration. In addition, liposomes can provide a method for forming an aqueous dispersion of hydrophobic drugs for intravenous delivery.
  • liposomes When liposomes are used to target encapsulated drugs to selected host tissues, and away from sensitive tissues, several techniques can be employed. These procedures involve manipulating the size of the liposomes, their net surface charge as well as the route of administration. More specific manipulations have included labeling the liposomes with receptors or antibodies for particular sites in the body.
  • the route of delivery of liposomes can also affect their distribution in the body. Passive delivery of liposomes involves the use of various routes of administration e.g., intravenous, subcutaneous and topical. Each route produces differences in localization of the liposomes.
  • Two common methods used to actively direct the liposomes to selected target areas are binding either antibodies or specific receptor ligands to the surface of the liposomes.
  • Antibodies are known to have a high specificity for their corresponding antigen and have been shown to be capable of being bound to the surface of liposomes, thus increasing the target specificity of the liposome encapsulated drug.
  • liposomes can be very useful in adapting these drugs for intravenous delivery.
  • Many hydrophobic drugs including cyclosporine, fall into this category because they cannot be easily dissolved in a water-based medium and must be dissolved in alcohols or surfactants which have been shown to cause toxic reactions in vivo.
  • Liposomes predominantly composed of lipids, with or without cholesterol, are nontoxic.
  • liposomes are made up of amphipathic molecules, they can entrap hydrophilic drugs in their interior space and hydrophobic molecules in their lipid bilayer.
  • a therapeutically effective cyclosporin intercalated liposome product has not been commercially available. It has thus been a desideratum to develop a liposomal cyclosporin containing a formulation which enables a high proportion of the active agent to be incorporated therein, and which is sufficiently stable on the shelf and in the blood of mammals.
  • This invention provides such a product. It is also desirable to provide for a formulation that offers an optimum therapeutic index, that is, the right combination of high effectiveness and low toxicity. This high therapeutic value can be obtained when the formulation has the proper pharmacological profile based on attainable pharmacokinetics.
  • Such liposomes are those that are found not only to be safe and efficacious, but are those that are stable in the blood of mammals.
  • an object of the present invention is to provide an improved liposome encapsulated cyclosporin formulation that has superior shelf life stability and reduced toxicity. It is also an object of the present invention to provide for a liposomal cyclosporin formula which is resistant to the loss of drug in the presence of whole (mammal) blood.
  • the liposomes are efficacious as immunosuppressive agents and in the treatment of drug resistant cancers.
  • the formulations include liposomes comprised of a phosphatidylcholine (PC), cholesterol, a phosphatidylglycerol (PG) and a cyclosporin.
  • PC phosphatidylcholine
  • PG phosphatidylglycerol
  • the mole ratios of the phosphatidylcholine, cholesterol, the phosphatidylglycerol and the cyclosporin are about 21:0.5:3:1 to 21:1.5:3:1 and 24:0.5:3:1 to 24:1.5:31 wherein the liposomes comprise unilamellar vesicles having a size less than 100 nm.
  • a liposome encapsulated cyclosporin which provides for a cyclosporin which associates to a significant degree with a liposomal/plasma fraction (vs. cell fraction) of blood as a function of time.
  • Liposomes having these properties are comprised of a phosphatidylcholine, cholesterol, dimyristoylphosphatidylglycerol (DMPG) and a cyclosporin. These liposomes are unilamellar and have a size less than 75 nanometers and are stable in whole mammal blood. Further provided are liposomes having increased therapeutic indices.
  • the compositions are stable upon injection into the blood stream of a mammal, preferably a human.
  • the preferred ratios of PC:chol:PG:cyclosporine A are from 28:1:3:1 to 40:1:3:1.
  • the preferred formulas are PC:chol:DMPG:CSAwherein the PC is hydrogenated soy phosphatidylcholine (HSPC) and the molar ratios are: 28:1:3:1, 30:1:3:1, 32:1:3:1, 34:1:3:1, 35:1:3:1, 36:1:3:1, and 40:1:3:1.
  • the liposomes of the invention as practiced herein are generally prepared by:
  • the invention provides a cyclosporin intercalated liposomal formulation which is stable on storage, contains a therapeutically effective amount of active ingredient, provides a liposomal cyclosporin formulation having reduced toxicity, and, in the preferred embodiment, provides a liposomal formulation which is stable in whole blood.
  • Whole blood stability is defined as having > 70% of cyclosporin in a plasma/liposomal fraction at four hours and where ⁇ 0.5 mg/ml of hemoglobin is released from red blood cells (RBC) to the plasma iposome fraction at four hours as determined using a modified version of Sigma's Drabkin assay kit. This test shows an improvement of lower concentration hemoglobin released in whole mammal blood of 10-fold to over 200-fold improvement over cyclosporine in cremophor EL.
  • RBC red blood cells
  • liposome refers to unilamellar vesicles or multilamellar vesicles such as are described in U.S. Patents 4,753,788 and 4,935,171, the contents of which are incorporated herein by reference.
  • encapsulation refers to the incorporation of the cyclosporin into the liposome membrane.
  • the process of preparing the formulation embodied in the present invention is initiated with the preparation of a solution from which the liposomes are formed. This is done by weighing out appropriate quantities of a phosphatidylcholine, cholesterol, a phosphatidylglycerol and a cyclosporin, preferably cyclosporin A, and dissolving them into an organic solvent, preferably chloroform and methanol in a 1 : 1 mixture. The solution is evaporated to form a solid lipid phase such as a film or powder, for example, with a rotary evaporator, spray dryer or other means.
  • the film or powder is then hydrated with an aqueous solution having a pH ranging from about 4.5 to about 9.5 to form a liposome dispersion.
  • the preferred aqueous solution for purposes of hydration is a buffered solution such as 9% sucrose/ 10 mM succinate or 10 mM phosphate buffer.
  • the preferred buffer is 9% sucrose, 10 mM succinate wherein the pH is about 6.5.
  • the lipid film or powder dispersed in buffer is heated from about 25°C to about 65°C, preferably at about 55°C.
  • Multilamellar liposomes are formed by agitation of the dispersion, preferably through the use of a thin-film evaporator apparatus such as is described in U.S. Patent 4,935,171 or through shaking or vortex mixing.
  • Unilamellar vesicles are formed by the application of a shearing force to an aqueous dispersion of the lipid solid phase, e.g., by sonication or the use of a homogenizing apparatus such as a Gaulin homogenizer or a French press. Shearing force can also be applied using either injection, freezing and thawing, dialyzing away a detergent solution from lipids, or other known methods used to prepare liposomes.
  • the size of the liposomes can be controlled using a variety of known techniques including the duration of shearing force.
  • the modified Gaulin homogenizing apparatus described in U.S. Patent 4,753,788 is employed to form unilamellar vesicles having diameters of less than 200 nanometers at a pressure of 3,000 to 10,000 psi and a temperature of about the aggregate transition temperature of the lipids.
  • Methods for the agitation or shearing of lipids to form multilamellar or unilamellar vesicles are known in the art and are not part of this invention per se.
  • Distearoylphosphatidylcholine DSPC
  • egg phosphatidylcholine egg PC
  • hydrogenated egg phoshatidylcholine HEPC
  • hydrogenated soy phosphatidylcholine HSPC
  • DSPC Distearoylphosphatidylcholine
  • egg PC egg phosphatidylcholine
  • HEPC hydrogenated egg phoshatidylcholine
  • HSPC hydrogenated soy phosphatidylcholine
  • HSPC hydrogenated soy phosphatidylcholine
  • suitable phosphatidylcholines include those obtained from soy beans or other plant sources, or those that are partially or wholly synthetic, such as dipalmitoylphosphatidylcholine. All of these are commercially available.
  • DMPG is the preferred phosphatidylglycerol for use in the invention.
  • Other negatively charged lipids can be used in combination with or in place of the phosphatidyl glycerol.
  • Other suitable negatively charged lipids for use in the present invention include, but are not limited to, dilaurylphosphatidylglycerol (DLPG), dipalmitoylphosphatidylglycerol (DPPG), and dimyristoylphosphatidic acid (DMPA). All of these are also commercially available.
  • the ratios of PC:chol:PG:CSA are from about 21:0.5:3:1 to about 21:1.5:3:1 and from about 24:0.5:3:1 to about 24:1.5:3:1.
  • the preferred formulation is about 24:1:3: 1.
  • the preferred lipids in this embodiment are DSPC and DMPG.
  • the preferred size is below 45 ⁇ m and the preferred percent entrapped cyclosporin is about 85% or greater.
  • the liposomes of this embodiment show improved shelf life stability, i.e., no significant visual aggregation for at least 9 weeks at 4°C.
  • the ratios of PC:chol:PG:CSA are from 28: 1 :3: 1 to 40: 1 :3: 1.
  • the preferred formulas in this embodiment are PC:chol:DMPG:cyclosporin wherein the PC is HSPC and the molar ratios are: 28:1:3:1, 30:1:3:1, 32:1:3:1, 34:1:3:1, 35:1:3:1, 36:1:3:1, and 40:1:3:1.
  • the preferred cyclosporin for use in the invention is cyclosporine A
  • the preferred size for liposomes in which stability in blood is desired is below 50 nm.
  • the preferred percent entrapped cyclosporin is about 85 % or greater.
  • the liposomes of the invention as practiced herein show improved shelf life stability, i.e., no significant (visual) aggregation for at least 9 weeks at 4°C.
  • the invention also provides a method for suppressing an immune response in a mammal by the delivery of a therapeutic or effective amount of liposomal cyclosporin formulation.
  • the formulations are useful for the treatment of autoimmune diseases and in the treatment of allograft patients.
  • a method for reducing multiple drug resistance of a cancer cell by delivering a therapeutic or effective amount of a cyclosporin, preferably cyclosporine, liposomal formulation to a mammal.
  • a cyclosporin preferably cyclosporine, liposomal formulation
  • the cyclosporin is used in a treatment combination with an antineoplastic or anticancer agent.
  • a method of inhibiting the growth of cancer cells is provided by delivering a therapeutic or effective amount of free cyclosporin or liposomal cyclosporin to cancer cells, preferably in a mammal. Since dosage regimens for cyclosporins are well known to medical practitioners, the amount of the liposomal cyclosporin formulations which is effective or therapeutic for the treatment of the above mentioned diseases or conditions in mammals and particularly humans will be apparent to those skilled in the art.
  • a series of liposome formulations containing cyclosporine were prepared.
  • DSPC, cholesterol, DMPG and cyclosporine (21:1.5:3:1, 21:1:3:1, 24:1.5:3:1 and 24:1:3:1 respectively) were dissolved in a mixture of chloroform and methanol (1:1 by volume) and the solution formed was dried under nitrogen until a dried film was obtained.
  • the lipid film was placed in a desiccator under vacuum for at least 8 hours to remove the residual organic solvent.
  • Unilamellar vesicles were formed by sonicating the solution for 15 minutes at 65 °C until a translucent solution was obtained. The solution was incubated at 65°C for 10 minutes. The solution was centrifuged at 3600 rpm for 10 minutes and the supernatant was collected. The concentration of lipids and cyclosporine was determined by HPLC. The size of the vesicles was determined by optical particle sizing. The results are listed in Table 1.
  • the cell pellet was adjusted to 1 x 10 5 cells/ml in RPMI-1640 + 20% FCS + 2% FCS and 1% pen-strep, and the plates were incubated for 24 hrs at 37°C. (Positive control wells only contained cells and media, and negative control wells contained cells, media, and 20 ⁇ l of 1.5M Tris buffer). After 20 hours of incubation, the plates were pulsed with 0.5 ⁇ Ci of 3 H-Thymidine per well and incubated for an additional 4 hours. Next, the cells were harvested using a Tomtec harvester and counted on a Betaplate scintillation counter. Linear regression analysis was used to determine the IC- 50's of the various cyclosporin. A treatments and the doxorubicin IC-50 values were graphed as a function of CsA concentration.
  • the cholesterol-containing liposomal formulations tested demonstrated a reversal of the MDR in P388/ADR cells. However, some of the formulations were more efficacious than others.
  • a DSPC:Chol:DMPG:CS A formulation (24: 1 : 3 : 1 ) was prepared as described in Example 1.
  • the following experiment was performed to compare the ability of various liposomal cyclosporin formulations, given in vivo, to suppress the splenic lymphocyte response to in vitro stimulation by concanavalin A (ConA) as compared to cyclosporine in complex L (CSA CreL, Sandimmune, SA). Mice were sacrificed and their spleens removed and placed in RPMI-1640 medium with 2% pen-strep (Gibco). A single cell suspension was made from each spleen by passing it through a 70 ⁇ m nylon mesh sieve (Falcon).
  • the sieve was rinsed with RPMI+2% pen-strep to obtain a 10 ml volume of cell suspension.
  • the splenic cell suspension was centrifuged at 1000 rpm for 8 min. and the supernatant was removed.
  • the red blood cells were lysed with 1 ml lysing buffer (Cardinal Assoc. lot #09406 exp. Jan 1997) for 1 min., then centrifuged at 10000 rpm for 8 min. and the supernatant was removed.
  • the cell pellet was resuspended in RPMI+5% FCS+1 pen-strep, and cell viability determined by trypan blue staining.
  • the cells were then adjusted to a cell concentration of about 5 x 10 ⁇ cells/ml.
  • the splenic lymphocytes were plated into the wells of a 96-well round bottom plate at 0.1 ml well (5 x 10 ⁇ cells/well).
  • Concanavalin A was diluted in PBS, aliquoted, and stored in a frozen state at -70° C prior to use. A 1 ml aliquot was thawed and diluted 1 :4 in RPM+5 % FCS + 1 % pen-strep. The stock solution was diluted in RPMI+5 %FCS + 1 % pen-strep to obtain working solutions of 3 ⁇ Ci H-Thymidine (ICN Radiochemicals) per well on day 2. The cells were harvested onto glassfibre filtermats on day 3 using a Tomtec cell harvester.
  • Lipid films or spray dried powder containing various mole ratios of lipids and CSA as shown in Tables 3 and 4 were prepared.
  • DSPC was used.
  • HSPC was used.
  • the formulations contained DSPC or HSPC, cholesterol, DMPG and cyclosporine A.
  • the spray dried powder or lipid films were hydrated with an aqueous buffer containing 9% sucrose in 10 mM succinate at pH 6.5 and heated to 55°C and dispersed. This mixture was further hydrated in a water bath at 55°C with stirring for 30 minutes.
  • Shear force was applied at temperatures above the transition temperature of the formulation with a modified Gaulin homogenizer (Gamble US Patent Number 4,753,788) at 4,000 - 12,000 psi to generate unilamellar liposomes having average median diameters (Microtract) as shown in Table 5. Samples were filtered at 50 - 65°C through a 0.22 ⁇ m filter composed of cellulose acetate. TABLE 3
  • the vial of whole blood was determined to be acceptable and used in the assay. If the plasma color was bright red it was determined that hemolysis had occurred and the affected tube of blood was be discarded.
  • the whole blood tested was pooled to collect the appropriate volume of blood needed to complete the assay.
  • To each ml of whole rat blood, 0.6 mis of a cyclosporin containing liposome formulation was added to mimic an equivalent dose of 80 mg/kg in rats (1.7 - 2.0 mg/ml CSA).
  • the exact amount of drug introduced (100% recovery) was calculated ([CSA] mg/ml *0.6 ml).
  • the samples were immediately vortexed for approximately 10 seconds and incubated in a water bath at 37°C for 4 hours.
  • each sample was vortex mixed again for about 10 seconds and centrifuged at 10,000 rpm for 5 minutes in a Brinkmann Eppendorf 5415 centrifuge.
  • the top plasma layer was removed and transferred via a glass Pasteur pipette to a test tube and the exact volume of plasma was recorded.
  • An aliquot of the plasma was then assayed for CSA by a HPLC.
  • the CSA content was then calculated for the plasma/liposome fraction ([CSA] mg/ml in plasma * plasma volume(ml)/mg total CSA added* 100) and was expressed as a percent of CSA recovered.
  • Table 5 It should be noted that 10 - 12% of the plasma volume was occluded in the red blood cell pellet and therefore not recoverable. The data presented in Table 5 was not corrected for the occluded volume such that the maximal percent of CSA recovered was at most 88 - 90%.
  • Example 6 Hemoglobin Release Test It is desirable to develop a liposomal formulation of cyclosporin A that is stable and does not lose its active ingredient when introduced to whole blood.
  • a hemoglobin release test was developed to screen candidate liposomal formulations containing cyclosporine A.
  • the assay involved quantitating the amount of hemoglobin (an indicator of red blood cell lysis or damage) present in a plasma fraction after incubation of rat whole blood with liposomal formulations of cyclosporin A at 37°C for 0, 1 or 4 hours followed by centrifugation at 10,000 rpm for 5 minutes.
  • the amount of hemoglobin released is related to the amount of loosely associated cyclosporin A in the liposomal formulations.
  • Rat (Fischer, male) whole blood was obtained via cardiac puncture and collected into tubes containing EDTA as an anticoagulant. The ensure hemolysis and/or cell damage has not occurred from the phlebotomy, for each tube of blood collected a small aliquot was centrifuged at 10,000 rpm for 5 minutes in a Brinkmann Eppendorf 5415 centrifuge. The red blood cells formed a pellet at the bottom of the tube and the plasma remained in a separate layer above the red blood cells after subjection to this treatment. The plasma fraction was examined for color. If the plasma color was straw yellow to light pink the vial of whole blood was acceptable and used in the assay. If the plasma color was bright red hemolysis had occurred and the affected tube of blood was discarded. Whole blood was tested as previously described was pooled to collect the appropriate volume of blood needed to complete the entire assay.
  • a cyclosporin containing liposome formulation was added to mimic an equivalent dose of 80 mg/kg in rats (1.7 - 2.0 mg/ml CSA).
  • a control sample was prepared with 1 ml of whole blood alone which was subjected to all the subsequent steps of the assay. The samples were immediately vortexed for 10 seconds and incubated in a water bath at 37°C for 4 hours. After the incubation was complete each sample was vortex mixed again for 10 seconds and centrifuged at 10,000 rpm for 5 minutes in a Brinkmann Eppendorf 5415 centrifuge or equivalent. The top plasma layer was removed and transferred via a glass Pasteur pipette to a test tube.
  • the preferred formulations are shown by combining the criteria of Tables 3 & 4 which indicate that the following range of formulas would achieve the necessary whole blood stability and lower hemoglobin release: 28: 1 :3: 1 to 40: 1 :3: 1.
  • the preferred formulations being: 28:1:3:1, 30:1:3:1, 32:1:3:1, 34: 1:3:1, 36:1:3: 1, 5 and 40:1:3:1 with HSPC used as the preferred phosphatidylcholine.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des formulations liposomales améliorées contenant de la cyclosporine encapsulée. Les liposomes selon l'invention sont efficaces en tant qu'agents immunosuppresseurs et dans le traitement de cancers pharmacorésistants. Lesdites formulations comprennent des liposomes constitués d'une phosphatidylcholine, de cholestérol, d'un phosphatidylglycérol et d'une cyclosporine. Dans un mode de réalisation, les rapports molaires entre la phosphatidylcholine, le cholestérol, le phosphatidylglycérol et la cyclosporine sont d'environ 21:0,5:3:1 à 21:1,5:3:1 et 24:0,5:3:1 à 24:1,5:31, lesdits liposomes comprenant des vésicules monocouches d'une taille inférieure à 100 nm. Dans un mode de réalisation préféré, les compositions sont stables lors de leur injection dans le sang d'un mammifère, de préférence un homme. Dans ce dernier mode de réalisation, les rapports préférés PC:chol:PG:CSA sont environ de 28:1:3:1 à 40:1:3:1. Les formules préférées sont: PC:chol:DMPG:CSA, où la PC est de la phosphatidylcholine de soja hydrogénée (HSPC) et les rapports molaires entre ces constituants sont: 28:1:3:1, 30:1:3:1, 32:1:3:1, 34:1:3:1, 35:1:3:1, 36:1:3:1, et 40:1:3:1. L'invention concerne également une cyclosporine encapsulée dans un liposome qui constitue une cyclosporine qui se lie, à un degré important, avec une fraction liposome/plasma (par opposition à la fraction cellulaire) du sang, en fonction du temps. Des liposomes ayant ces propriétés sont constitués de phosphatidylcholine, de cholestérol, de dimyristoylphosphatidylglycerol et de cyclosporine. Ces liposomes sont monocouches, ont une taille inférieure à 75 nanomètres et sont stables dans le sang total d'un mammifère. L'invention concerne également des liposomes présentant un indice thérapeutique augmenté. Les liposomes selon l'invention sont stables au stockage, contiennent une quantité thérapeutiquement efficace d'une cyclosporine, constituent une formulation liposomale contenant de la cyclosporine ayant une toxicité réduite, et, dans le mode de réalisation préféré, constituent une formulation liposomale stable dans le sang total.
PCT/US1996/009053 1995-06-07 1996-06-06 Formulations liposomales contenant de la cyclosporine, utilisees comme agents immunosuppresseurs et pour le traitement de multiples cas pharmacoresistants WO1996040064A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU60479/96A AU6047996A (en) 1995-06-07 1996-06-06 Liposomal cyclosporin formulations as agents for immunosuppr ession and multiple drug resistant indications

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/472,635 US5656287A (en) 1995-06-07 1995-06-07 Liposomal cyclosporin formulations as agents for immunosuppression and multiple drug resistant indications
US08/472,635 1995-06-07
US08/475,294 1995-06-07
US08/475,294 US5693336A (en) 1995-06-07 1995-06-07 Blood stable liposomal cyclosporin formulations

Publications (1)

Publication Number Publication Date
WO1996040064A1 true WO1996040064A1 (fr) 1996-12-19

Family

ID=27043845

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/009053 WO1996040064A1 (fr) 1995-06-07 1996-06-06 Formulations liposomales contenant de la cyclosporine, utilisees comme agents immunosuppresseurs et pour le traitement de multiples cas pharmacoresistants

Country Status (2)

Country Link
AU (1) AU6047996A (fr)
WO (1) WO1996040064A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4430592A1 (de) * 1994-08-20 1996-02-22 Max Delbrueck Centrum Liposomale Zubereitung, ihre Herstellung und ihre Verwendung
WO1998036735A1 (fr) * 1997-02-20 1998-08-27 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. Spa Composition pharmaceutique aqueuse comprenant un principe actif essentiellement insoluble dans l'eau
WO2004050690A1 (fr) 2002-12-02 2004-06-17 Xenome Ltd Nouveaux peptides (-i) de $g(x)-conotoxine
US6794361B1 (en) 1998-10-02 2004-09-21 The University Of Queensland Peptides
US7507717B2 (en) 2002-12-02 2009-03-24 Xenome Ltd. Type II chi-conotoxin peptides (noradrenaline transporter inhibitors)
WO2020002353A1 (fr) 2018-06-27 2020-01-02 Breath Therapeutics Gmbh Compositions pharmaceutiques sous forme lyophilisée

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018104A1 (fr) * 1991-04-19 1992-10-29 Vestar, Inc. Formulation et procedes pharmaceutiques
DE4402867C1 (de) * 1994-01-31 1995-06-14 Rentschler Arzneimittel Liposomen enthaltend darin verkapselte Proteine, Verfahren zu ihrer Herstellung sowie diese Liposomen enthaltende pharmazeutische und kosmetische Zubereitungen
EP0697214A1 (fr) * 1994-07-19 1996-02-21 Vestar, Inc. Formulations pharmaceutiques avec de la cyclosporine liposomale

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018104A1 (fr) * 1991-04-19 1992-10-29 Vestar, Inc. Formulation et procedes pharmaceutiques
DE4402867C1 (de) * 1994-01-31 1995-06-14 Rentschler Arzneimittel Liposomen enthaltend darin verkapselte Proteine, Verfahren zu ihrer Herstellung sowie diese Liposomen enthaltende pharmazeutische und kosmetische Zubereitungen
EP0697214A1 (fr) * 1994-07-19 1996-02-21 Vestar, Inc. Formulations pharmaceutiques avec de la cyclosporine liposomale

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
S. VENKATARAM ET AL.: "PHARMACOKINETICS OF TWO ALTERNATIVE DOSAGE FORMS FOR CYCLOSPORINE: LIPOSOMES AND INTRALIPID", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 79, no. 3, March 1990 (1990-03-01), WASHINGTON (US), pages 216 - 219, XP000101621 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399094B1 (en) 1994-08-20 2002-06-04 Martin Brandl Unilamellar liposomal preparations with high active substance content
DE4430592A1 (de) * 1994-08-20 1996-02-22 Max Delbrueck Centrum Liposomale Zubereitung, ihre Herstellung und ihre Verwendung
KR100515249B1 (ko) * 1997-02-20 2005-09-16 아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이 고 수불용성의 활성 성분을 함유한 수용성 약학적 조성물
BG64367B1 (bg) * 1997-02-20 2004-12-30 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Метод за получаване на воден фармацевтичен състав
AU740619B2 (en) * 1997-02-20 2001-11-08 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Aqueous pharmaceutical composition comprising an active ingredient which is highly insoluble in water
US6337087B1 (en) * 1997-02-20 2002-01-08 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Aqueous pharmaceutical composition comprising an active ingredient which is highly insoluble in water
WO1998036735A1 (fr) * 1997-02-20 1998-08-27 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. Spa Composition pharmaceutique aqueuse comprenant un principe actif essentiellement insoluble dans l'eau
US7326682B2 (en) 1998-10-02 2008-02-05 Xenome Limited Conotoxin peptides
US6794361B1 (en) 1998-10-02 2004-09-21 The University Of Queensland Peptides
US7994128B2 (en) 1998-10-02 2011-08-09 Xenome Limited Conotoxin peptides useful as inhibitors of neuronal amine transporters
WO2004050690A1 (fr) 2002-12-02 2004-06-17 Xenome Ltd Nouveaux peptides (-i) de $g(x)-conotoxine
US7507717B2 (en) 2002-12-02 2009-03-24 Xenome Ltd. Type II chi-conotoxin peptides (noradrenaline transporter inhibitors)
US7851444B2 (en) 2002-12-02 2010-12-14 Xenome Ltd. χ-conotoxin peptides (-1)
EP2386566A2 (fr) 2002-12-02 2011-11-16 Xenome Ltd Peptides de chi-conotoxine (II)
EP2412719A1 (fr) 2002-12-02 2012-02-01 Xenome Ltd Pptides de chi-conotoxine
WO2020002353A1 (fr) 2018-06-27 2020-01-02 Breath Therapeutics Gmbh Compositions pharmaceutiques sous forme lyophilisée

Also Published As

Publication number Publication date
AU6047996A (en) 1996-12-30

Similar Documents

Publication Publication Date Title
US5688525A (en) Pharmaceutical formulation and process
US4776991A (en) Scaled-up production of liposome-encapsulated hemoglobin
JP2958774B2 (ja) アンホテリシンｂリポソームの改良調整法
US5874104A (en) Treatment of systemic fungal infections with phospholipid particles encapsulating polyene antibiotics
EP1143933B1 (fr) Nouvelles formulations de structures cochleaires isolees dans des hydrogels, procede de preparation et utilisation de celles-ci pour administrer des molecules biologiquement utiles
AU740111B2 (en) Hyaluronic drug delivery system
JPH0753661B2 (ja) プロ―リポソーム組成物及びリポソームの水性分散物を作る方法
CA2150832C (fr) Formulation antibiotique et utilisation pour infections bacteriennes
JP2002507966A (ja) 薬学的組成物の調製
JP2002505307A (ja) 薬学的組成物およびその使用
US5693336A (en) Blood stable liposomal cyclosporin formulations
WO2009062299A1 (fr) Compositions de liposomes stabilisés par un gel, leurs procédés de préparation et leurs utilisations
IE911231A1 (en) Long-acting liposome peptide pharmaceutical products and¹processes for the preparation thereof
US5683714A (en) Liposomal cyclosporin pharmaceutical formulation
WO1996040064A1 (fr) Formulations liposomales contenant de la cyclosporine, utilisees comme agents immunosuppresseurs et pour le traitement de multiples cas pharmacoresistants
US5656287A (en) Liposomal cyclosporin formulations as agents for immunosuppression and multiple drug resistant indications
EP0697214A1 (fr) Formulations pharmaceutiques avec de la cyclosporine liposomale
JP4694776B2 (ja) 微小粒子組成物又はリポソーム製剤
Venkatesh A review on: Liposomes
CN105749291B (zh) 一种转移消失蛋白脂质体复合物及其制备方法和应用
JPS63501569A (ja) アルファトコフェロ−ルをベ−スとした小胞体
Reddy et al. International Journal of Indigenous Herbs and Drugs
CA1333049C (fr) Vesicules a base d'alpha-tocopherol
Aramwit The effect of serum albumin and Pluronics® on the aggregation state and toxicity of polyene macrolides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载